01Approach to the Critical Patient/attcp38

Immediate priorities

›Pregnancy + rubella infection — highest priority scenario

›Immediately establish gestational age

›CRS risk up to 85% if infection in first 12 weeks of gestation

›CRS risk 25% by second trimester; rare after 20 weeks

›Urgent OB/MFM referral for any susceptible pregnant patient with exposure or confirmed infection

›Life-threatening complications requiring escalation

›Encephalitis presentation

›Altered mental status

›Seizures

›Focal neurologic deficits

›Thrombocytopenic purpura with active bleeding

›Petechiae and purpura

›Platelet count threshold for IVIG consideration

›Signs of meningismus requiring urgent lumbar puncture planning

›Isolation and infection control priorities

›Droplet precautions immediately on clinical suspicion

›Infectious period: 7 days before to 14 days after rash onset

›Standard surgical mask for patient transport

›Identify and protect pregnant contacts

›Any pregnant healthcare worker or visitor: immediate removal from exposure area

›Urgently screen pregnant household contacts for immunity

Monitoring and targets

›Vital sign targets

›Temperature trend monitoring

›Low-grade fever typical: usually below 38.5 C

›High fever suggests alternative diagnosis or superinfection

›Neurologic status monitoring

02History/hx50

Rash characterization

›Onset pattern

›Face first, spreading cephalocaudally to trunk then extremities over 24 hours

›Duration typically 3 days (range 1-5 days)

›Erythematous maculopapular quality

›Non-confluent, non-vesicular

›Prodromal symptoms preceding rash by up to 5 days

›Low-grade fever

›Headache

›Malaise

›Sore throat

›Cough and rhinorrhea

›Mild conjunctivitis

Lymphadenopathy history

›Posterior lymphadenopathy pattern

›Posterior auricular nodes

›Posterior cervical nodes

›Suboccipital nodes

›Onset often precedes rash by 5-8 days

Joint symptoms

›Arthralgias and arthritis pattern

›Particularly in adolescent girls and adult women

›Up to 70% of adult women affected

›Small joints of hands, wrists, knees

›May persist for weeks after rash resolves

Exposure and vaccination history

›Exposure history

›Travel to endemic areas: Africa, Southeast Asia, Eastern Mediterranean

03Physical Exam/exam44

Vitals and general appearance

›Vital sign pattern

›Temperature: low-grade typically below 38.5 C

›Tachycardia if febrile

›Respiratory rate and oxygen saturation: normal in uncomplicated disease

›General appearance

›Generally well-appearing (distinguishes from measles)

›Mild-to-moderate distress in adults with arthralgias

Skin exam

›Rash characteristics

›Generalized erythematous maculopapular rash

›Distribution: face first, then trunk, then extremities

›Non-confluent lesions

›Fades in approximately 3 days

›Forchheimer spots: petechial spots on soft palate (not pathognomonic)

›Concerning skin findings

›Petechiae or purpura: suggests thrombocytopenic purpura complication

›Blueberry muffin rash in neonates: CRS dermal erythropoiesis

Lymph node exam

›Posterior lymphadenopathy (hallmark finding)

›Posterior auricular nodes: tender, enlarged

›Posterior cervical nodes: tender, enlarged

›Suboccipital nodes: tender, enlarged

›Distinguishing feature: anterior cervical predominance favors measles or EBV

Head and neck exam

›Eye exam

›Mild conjunctivitis: more common in adults

›No conjunctival hemorrhage

04Differential Diagnosis/ddx33

Life-threatening mimics

›Measles (rubeola)

›ICD-10: B05.9

›Distinguishing features: higher fever, severe cough-coryza-conjunctivitis triad, Koplik spots, confluent rash, sicker-appearing patient

›Dengue fever

›ICD-10: A90

›Travel to tropical areas, high fever, retro-orbital pain, thrombocytopenia, hemorrhagic manifestations

›Meningococcemia

›ICD-10: A39.4

›Petechial or purpuric rash, septic shock, meningismus

Common exanthem mimics

›Parvovirus B19 erythema infectiosum

›ICD-10: B08.3

›Slapped-cheek rash, reticular rash on extremities, arthralgias

›Frequently clinically indistinguishable from rubella; can circulate concurrently

›HHV-6 roseola infantum

›ICD-10: B08.20

›High fever followed by rash after defervescence, primarily children under 2 years

›Scarlet fever

›ICD-10: A38.9

›Sandpaper-textured rash, pharyngitis, strawberry tongue, Pastia lines

›Enteroviral exanthem

›ICD-10: B34.1

›Nonspecific maculopapular rash, GI symptoms, hand-foot-mouth pattern

›Drug reaction

›ICD-10: L27.0

›Temporal relationship to new medication, pruritus, eosinophilia

›EBV or CMV mononucleosis

05Laboratory Tests/lt31

Serologic diagnosis

›Rubella-specific IgM (enzyme immunoassay)

›Most common initial diagnostic test

›Only approximately 50% positive at rash onset: peaks at day 5

›If negative and specimen collected within 5 days of rash, repeat testing is required

›False positives: rheumatoid factor, parvovirus IgM, heterophile antibodies

›Positive predictive value as low as 1.4% in low-incidence settings

›Rubella-specific IgG: acute and convalescent

›Fourfold or greater rise between specimens 14-21 days apart is diagnostic

›Single positive IgG indicates prior immunity (past infection or vaccination)

›IgG avidity testing

›High avidity: past infection or remote vaccination

›Low avidity: recent infection (within 3 months)

›Useful in ambiguous cases during pregnancy

Molecular testing

›RT-PCR for rubella RNA

›Specimens: nasal swab, throat swab, or urine

›Most sensitive within 3 days of rash onset

›Gold standard for confirmation of active infection

›Available primarily through public health and CDC laboratories

›Genotyping via sequencing: distinguishes vaccine virus from wild-type; essential for epidemiologic tracking

Hematologic and metabolic labs

›Complete blood count

›Leukopenia: common in acute rubella

›Thrombocytopenia: complication in approximately 1 in 3,000 cases

›Platelet count below 20 x10^9/l: threshold for active bleeding concern

›Liver function tests

›Hepatic dysfunction reported in approximately 0.3% of cases

06Diagnostic Tests/dt43

Scoring Systems

›No validated emergency department scoring system exists for rubella

›Clinical diagnosis unreliable: laboratory confirmation mandatory for all suspected cases

›Severity stratification by complication profile

›Uncomplicated: fever, rash, lymphadenopathy, arthralgias

›Complicated: thrombocytopenic purpura (1:3,000) or encephalitis (1:6,000)

›Pregnancy-related: CRS risk stratified by gestational age at infection

MRI

›Brain MRI indications

›Altered mental status or seizures in postnatal rubella: encephalitis evaluation

›White matter changes in post-infectious encephalomyelitis

›Cortical edema pattern

›CRS with microcephaly or neurologic signs

›Periventricular calcifications

›Cortical malformations

›Lissencephaly or pachygyria reported in severe CRS

›Progressive rubella panencephalitis (rare)

›Diffuse white matter signal abnormalities

›Cortical and subcortical atrophy

CT

›Head CT indications

›Acute encephalitis with seizures when MRI not immediately available

›Exclude space-occupying lesion before lumbar puncture

›Cerebral edema assessment

›CRS evaluation

›Intracranial calcifications

›Microcephaly quantification

›Long bone radiographs in CRS

07Disposition/dispo30

Discharge criteria

›Discharge suitability for uncomplicated postnatal rubella

›Vast majority of postnatal rubella cases: mild, self-limited, manageable at home

›Normal mental status

›No active bleeding or thrombocytopenic purpura

›Adequate hydration and oral intake

›Reliable follow-up arranged

›Discharge instructions must include

›Isolation: exclude from school or work for 7 days after rash onset

›Avoid contact with pregnant women during infectious period

›Return precautions documented

Admission criteria

›Hospital admission indications

›Encephalitis: altered mental status, seizures, focal deficits

›Thrombocytopenic purpura with active bleeding or platelet count below 20 x10^9/l

›Severe dehydration

›Pregnant patient with confirmed rubella requiring urgent inpatient evaluation and MFM workup

›Suspected CRS in neonate

Consultation and reporting

›Mandatory public health reporting

›Report all suspected rubella cases to local and state health department immediately

›Rubella is a nationally notifiable disease in the United States

›Cases confirmed by laboratory testing trigger outbreak investigation

›Specialist consultation triggers

›OB/GYN or MFM: any pregnant woman with rubella exposure or confirmed infection

›Infectious disease: confirmed or suspected rubella given elimination-era rarity

›Pediatrics or neonatology: suspected CRS

›Ophthalmology, cardiology, audiology: CRS multi-system evaluation

08Treatment/t52

Supportive care

›No specific antiviral therapy for rubella

›Acetaminophen for fever and arthralgias

›325-650 mg orally every 4-6 hours as needed

›Maximum 3,000 mg per 24 hours in adults (conservative dosing)

›NSAIDs for arthralgias in non-pregnant patients

›Ibuprofen 400-600 mg orally every 6-8 hours with food

›Contraindicated in pregnancy

›Naproxen 250-500 mg orally twice daily as alternative

›Oral hydration encouraged

›Bed rest during febrile phase

Thrombocytopenic purpura management

›Thrombocytopenia treatment

›Usually self-limiting: observation appropriate for mild cases without bleeding

›IVIG for severe thrombocytopenia with active bleeding

›IVIG 1 g/kg intravenously over 6-8 hours

›May repeat once after 24-48 hours if inadequate response

›Target platelet count above 30 x10^9/l in stable patient

›Above 50 x10^9/l if active bleeding

›Corticosteroids: considered as alternative or adjunct in refractory cases

›Prednisone 1 mg/kg orally per day for 5-7 days

›Platelet transfusion: reserved for life-threatening hemorrhage

Encephalitis management

›Anticonvulsant therapy for seizures

›Lorazepam 0.1 mg/kg IV for acute seizure control

›Maximum 4 mg per dose

›May repeat once after 5 minutes if seizure continues

›Levetiracetam for ongoing seizure prophylaxis

09Special Populations/sp55

Pregnancy

›CRS risk and gestational age

›First 12 weeks: CRS risk up to 85% (highest risk period)

›Cardiac defects, cataracts, sensorineural hearing loss most severe

›Risk of spontaneous abortion and stillbirth increased

›13-16 weeks: CRS risk approximately 54%

›Isolated sensorineural hearing loss most common

›17-20 weeks: CRS risk approximately 25%

›After 20 weeks: CRS risk rare, sensorineural hearing loss only

›CRS clinical manifestations

›Sensorineural hearing loss: most common CRS manifestation (60-90% of affected infants)

›Congenital heart disease: PDA, peripheral pulmonary artery stenosis, VSD

›Ocular defects: cataracts, glaucoma, pigmentary retinopathy

›Neurologic: microcephaly, developmental delay, intellectual disability

›Hematologic: thrombocytopenia, blueberry muffin rash (dermal erythropoiesis)

›Hepatic: hepatosplenomegaly, jaundice within 24 hours of birth

›Diagnostic approach in pregnancy

›Maternal rubella IgM and IgG with avidity testing

›Amniocentesis RT-PCR: if maternal infection confirmed in first or early second trimester

›Serial fetal ultrasound for structural abnormalities

›Ophthalmologic exam, echocardiography, and audiology testing for confirmed CRS

›Management considerations

›No safe antiviral therapy in pregnancy

›Immunoglobulin: not routinely recommended; does not reliably prevent CRS

›MMR: absolutely contraindicated in pregnancy (live attenuated vaccine)

›Termination counseling: indicated for confirmed infection before 16-18 weeks given high CRS risk

Geriatric

›Rubella in older adults

10Background/b51

Epidemiology

›Global burden

›Rubella virus (genus Rubivirus, family Matonaviridae) causes approximately 100,000 CRS cases annually worldwide

›WHO global rubella elimination target: ongoing effort through expanded immunization programs

›Elimination achieved in Americas (2015), Western Pacific, and European regions

›Endemic transmission continues in Africa and parts of Asia

›United States epidemiology

›Rubella declared eliminated from the United States in 2004

›Fewer than 10 cases reported annually since elimination: travel-associated and sporadic

›CRS: fewer than 5 cases reported per year in post-elimination era

›Risk populations: unvaccinated immigrants from endemic countries

›Pre-vaccine era

›Last major US epidemic 1964-1965: approximately 12.5 million rubella cases

›1964-1965 epidemic resulted in approximately 20,000 CRS cases, 8,000 deaths, 11,000 cases of deafness, 3,500 cases of blindness

›MMR vaccine introduction in 1969 followed by dramatic decline in cases

Pathophysiology

›Transmission and incubation

›Transmission: respiratory droplets from nasopharyngeal secretions

›Contagiousness: infectious from 7 days before to 14 days after rash onset

›Incubation period: 14-21 days (mean 16-18 days)

›Secondary attack rate in susceptible household contacts: approximately 10-30%

›Viral pathogenesis in postnatal infection

›Initial replication in nasopharyngeal lymphoid tissue

›Viremia allows dissemination to skin, joints, and lymph nodes

›Rash mediated by immune complex deposition and cell-mediated immune response

›Lymphadenopathy precedes rash due to viral replication in lymphoid tissue

›Fetal pathogenesis in CRS

›Maternal viremia seeds placenta via hematogenous spread

11Patient Discharge Instructions/pdi30

copy discharge instructions

›Your diagnosis: Rubella (German Measles)

›Rubella is a viral infection that usually causes a mild rash, low-grade fever, and swollen lymph nodes behind your ears and neck

›Most people recover fully within 7-10 days without any treatment

›There is no specific antiviral medicine for rubella; treatment focuses on relieving symptoms

›Medications at home

›Take acetaminophen (Tylenol) 325-650 mg every 4-6 hours as needed for fever or joint pain

›Do not exceed 3,000 mg of acetaminophen in 24 hours

›If you are not pregnant, ibuprofen (Advil) 400-600 mg every 6-8 hours with food is also an option for joint pain

›Do NOT take ibuprofen or aspirin if you are pregnant

›Stay home and away from others

›You are contagious from 7 days before to 14 days after the rash appears

›Stay home from school or work for at least 7 days after your rash first appeared

›Avoid all contact with pregnant women during this time: rubella can cause serious birth defects

›If a pregnant woman in your household was exposed, she needs to see her doctor immediately

›Hydration and rest

›Drink plenty of fluids: water, juice, or soup

›Rest while you have a fever

›Return to the emergency department immediately if you develop

›Unusual bruising, small red or purple spots on the skin (petechiae or purpura), or unexplained bleeding

›Severe headache, confusion, difficulty thinking clearly, or difficulty walking

›Seizure or loss of consciousness

›Neck stiffness

›Worsening symptoms after 5-7 days instead of improving

›Vaccination for household contacts

›Any family member who has not had the MMR vaccine should speak with their doctor about getting vaccinated

›MMR vaccine should NOT be given to pregnant women

›After the MMR vaccine, women should avoid becoming pregnant for 28 days

12References/r21

Guidelines and key sources

›Winter AK, Moss WJ. Rubella. Lancet. 2022; PMID 35367004

›Comprehensive review of rubella epidemiology, pathogenesis, diagnosis, and management

›Primary source for CRS risk by trimester, complication rates, and diagnostic algorithm

›Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA. Rubella. Lancet. 2015; PMID 25576992

›Landmark review covering global elimination progress, pathophysiology, and vaccine efficacy

›Banatvala JE, Brown DW. Rubella. Lancet. 2004; PMID 15064032

›Classic review establishing foundation for CRS natural history and clinical management

›McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: ACIP Summary Recommendations. MMWR Recomm Rep. 2013; PMID 23760231

›ACIP vaccination schedule, immunity documentation, and post-exposure management recommendations

›Young MK, Cripps AW, Nimmo GR, van Driel ML. Post-Exposure Passive Immunisation for Preventing Rubella and Congenital Rubella Syndrome. Cochrane Database Syst Rev. 2015

›Evidence review concluding insufficient data to support routine immunoglobulin prophylaxis

›Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by IDSA and ASM. Clin Infect Dis. 2024

›Diagnostic testing guidance including RT-PCR indications, specimen types, and interpretation caveats

›Ou AC, Zimmerman LA, Alexander JP, et al. Progress Toward Rubella and CRS Elimination - Worldwide, 2012-2022. MMWR Morb Mortal Wkly Rep. 2024; PMID 38421933

›Global elimination progress, remaining endemic regions, and post-elimination surveillance

›Three Cases of Congenital Rubella Syndrome in the Postelimination Era - Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep. 2013; PMID 23535689

›Post-elimination era CRS surveillance illustrating ongoing risk in unvaccinated populations

›De Melo LC, Rugna MM, Duraes TA, et al. Congenital Rubella Syndrome in the Post-Elimination Era: Why Vigilance Remains Essential. J Clin Med. 2025; PMID 40507747

›Current evidence on CRS in elimination settings; argues for sustained surveillance and vaccination

›CDC Adult Immunization Schedule by Age (Addendum updated July 2, 2025). ACIP 2025

›Updated MMR dosing guidance for adults including catch-up vaccination recommendations

Evidence & Review

Evidence & Review